Insider · CIK 0001772233
Yishan Li
Files at BLSM (BlossomHill Therapeutics, Inc.). First filing -, latest -.
In brief
Yishan Li files SEC Form 4 as chair, director and 10% owner at BLSM (BlossomHill Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Yishan Li has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Common Stockindirect: By The Li and Cui Family Trust | +1,600,682 | - | - | 1,600,682 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Common Stockindirect: By The Li and Cui Family Trust | +113,435 | - | - | 1,714,117 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Common Stockindirect: By RongShan, LLC | +124,779 | - | - | 124,779 | Aug 10, 2026 |
| Aug 6, 2026 | BLSM BlossomHill Therapeutics, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +112,701 | $0.00 | $0 | 112,701 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Series Angel Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -1,600,682 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -113,435 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: By RongShan, LLC | -124,779 | - | - | 0 | Aug 10, 2026 |
Questions about Yishan Li
Answered from the filings on this page, as of the latest one.
Is Yishan Li buying or selling?
Yishan Li has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Yishan Li's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Yishan Li has 0.
Where does Yishan Li file Form 4?
Yishan Li has filed Form 4 at BLSM (BlossomHill Therapeutics, Inc.) as Executive Chairman. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.